Bain Capital Life Sciences Investors, LLC, 10% Owner at Kailera Therapeutics, Inc. (KLRA), bought 1,562,500 shares at $16.00 ($25.0M) on 2026-04-20, disclosed to the SEC on 2026-04-20.
Bain Capital Life Sciences Investors purchased $25M worth of KLRA at $16.00, marking the largest insider purchase in the company's history. This significant bet by a major shareholder follows the company's successful IPO and positive analyst coverage of its weight-loss drug pipeline.
The stock is currently trading 12.81% below its 52-week high of $28.23 and just 3.88% above its 52-week low of $23.69, reflecting a pullback from recent IPO highs.
William Blair initiated coverage on May 13, 2026, highlighting KLRA as a potential challenger in the weight-loss market; the company completed its IPO on May 1, 2026, and was added to the NASDAQ Composite Index; finally, Bain Capital's $25M purchase on April 20, 2026, represents the largest insider trade in the company's history.
The company carries a negative forward P/E of -5.6, indicating it is not yet profitable; additionally, the stock faces intense competition from established players like Eli Lilly and Novo Nordisk in the obesity market.
Negative factors outweigh the positive ones.
| Filing → |
| OLMA | BUY | 2025-01-13 | $1.7M | — | Filing → |
| ANNX | BUY | 2023-05-30 | $639K | — | Filing → |
| RPID | BUY | 2021-07-21 | $2.0M | — | Filing → |